Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COLL Collegium Pharmaceutical	$29.83 +0.8%	$28.57	$23.23 ▼ $42.29	$958.50M	0.63	405,163 shs	669,952 shs
CRLBF Cresco Labs	$0.43 -10.1%	$0.66	$0.43 ▼ $2.05	$211.92M	1.47	672,738 shs	494,321 shs
PAHC Phibro Animal Health	$23.88 -0.3%	$21.85	$16.16 ▼ $26.55	$967.95M	0.74	207,387 shs	247,450 shs
RCUS Arcus Biosciences	$8.67 +1.8%	$8.74	$6.50 ▼ $18.98	$912.73M	0.83	867,491 shs	1.33 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COLL Collegium Pharmaceutical	+0.78%	+2.23%	+1.22%	-0.73%	-7.22%
CRLBF Cresco Labs	-10.08%	-13.33%	-37.26%	-40.88%	-72.96%
PAHC Phibro Animal Health	-0.33%	-0.21%	+2.71%	+9.04%	+36.61%
RCUS Arcus Biosciences	+1.54%	-6.32%	+0.35%	-3.13%	-45.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COLL Collegium Pharmaceutical	4.1011 of 5 stars	3.4	1.0	0.0	3.0	2.7	0.8	2.5
CRLBF Cresco Labs	0.3938 of 5 stars	0.0	3.0	0.0	0.0	0.6	0.0	1.3
PAHC Phibro Animal Health	3.8525 of 5 stars	0.8	4.0	2.5	1.1	2.8	3.3	2.5
RCUS Arcus Biosciences	1.5526 of 5 stars	4.5	0.0	0.0	0.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COLL Collegium Pharmaceutical	2.75	Moderate Buy	$43.75	46.66% Upside
CRLBF Cresco Labs	3.00	Buy	N/A	N/A
PAHC Phibro Animal Health	1.67	Reduce	$20.80	-12.90% Downside
RCUS Arcus Biosciences	2.90	Moderate Buy	$24.13	178.42% Upside

Current Analyst Ratings Breakdown

Latest CRLBF, PAHC, RCUS, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/3/2025	CRLBF Cresco Labs	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Moderate Buy
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
4/23/2025	RCUS Arcus Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $14.00
4/15/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$20.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COLL Collegium Pharmaceutical	$631.45M	1.52	$12.33 per share	2.42	$7.10 per share	4.20
CRLBF Cresco Labs	$724.34M	0.29	N/A	N/A	$0.79 per share	0.55
PAHC Phibro Animal Health	$1.02B	0.95	$2.11 per share	11.30	$6.34 per share	3.77
RCUS Arcus Biosciences	$258M	3.56	N/A	N/A	$5.30 per share	1.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COLL Collegium Pharmaceutical	$69.19M	$1.22	24.45	4.96	N/A	6.61%	99.08%	15.14%	8/6/2025 (Estimated)
CRLBF Cresco Labs	-$74.44M	-$0.24	N/A	N/A	N/A	-11.86%	-21.77%	-6.00%	8/6/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	30.62	11.37	0.45	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$4.19	N/A	N/A	N/A	-258.94%	-70.58%	-32.97%	8/4/2025 (Estimated)

Latest CRLBF, PAHC, RCUS, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/30/2025	Q1 2025	CRLBF Cresco Labs	-$0.03	-$0.04	-$0.01	-$0.04	$164.37 million	$165.76 million
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
CRLBF Cresco Labs	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	2.01%	N/A	61.54%	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Latest CRLBF, PAHC, RCUS, and COLL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COLL Collegium Pharmaceutical	3.30	1.08	1.01
CRLBF Cresco Labs	1.63	2.75	1.98
PAHC Phibro Animal Health	2.67	2.91	1.23
RCUS Arcus Biosciences	0.09	5.37	5.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COLL Collegium Pharmaceutical	N/A
CRLBF Cresco Labs	0.05%
PAHC Phibro Animal Health	99.34%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
COLL Collegium Pharmaceutical	2.51%
CRLBF Cresco Labs	N/A
PAHC Phibro Animal Health	50.07%
RCUS Arcus Biosciences	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	31.33 million	Optionable
CRLBF Cresco Labs	2,900	491.02 million	N/A	Not Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	95.72 million	Optionable

CRLBF, PAHC, RCUS, and COLL Headlines

Recent News About These Companies

The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

June 13, 2025 | fiercebiotech.com

Arcus Biosciences (NYSE:RCUS) Shares Down 3.8% - What's Next?

June 11, 2025 | marketbeat.com

Stock Traders Purchase Large Volume of Call Options on Arcus Biosciences (NYSE:RCUS)

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Comments on RCUS FY2026 Earnings

June 11, 2025 | americanbankingnews.com

Arcus Biosciences Announces New Employment Inducement Grants

June 10, 2025 | businesswire.com

Research Analysts Offer Predictions for RCUS FY2026 Earnings

June 10, 2025 | marketbeat.com

H.C. Wainwright maintains Buy rating for Arcus Biosciences stock

June 4, 2025 | investing.com

Arcus Biosciences, Inc. (NYSE:RCUS) Short Interest Up 25.2% in May

June 4, 2025 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Trading 10.6% Higher - Here's What Happened

June 4, 2025 | marketbeat.com

Nuveen Asset Management LLC Has $1.96 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS)

June 4, 2025 | marketbeat.com

Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg

June 2, 2025 | biospace.com

Arcus unveils kidney cancer data as it eyes Phase III challenge to Merck’s Welireg

June 2, 2025 | thepharmaletter.com

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of ...

June 1, 2025 | gurufocus.com

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

June 1, 2025 | businesswire.com

Arcus Biosciences (NYSE:RCUS) Stock Price Down 8.6% - Time to Sell?

May 31, 2025 | marketbeat.com

Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

May 30, 2025 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

May 27, 2025 | businesswire.com

Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Millennium Management LLC

May 25, 2025 | marketbeat.com

Arcus Biosciences describes new c-Kit inhibitors

May 24, 2025 | bioworld.com

Woodline Partners LP Purchases 45,497 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

May 22, 2025 | marketbeat.com

Why Precision BioSciences, Inc.’s (DTIL) Stock Is Down 9.90%

May 15, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRLBF, PAHC, RCUS, and COLL Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

$29.83 +0.23 (+0.78%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$29.81 -0.02 (-0.07%)

As of 06/20/2025 05:01 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Cresco Labs OTCMKTS:CRLBF

$0.43 -0.05 (-10.08%)

As of 06/20/2025 03:59 PM Eastern

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.

Phibro Animal Health NASDAQ:PAHC

$23.88 -0.08 (-0.33%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$23.89 +0.01 (+0.04%)

As of 06/20/2025 04:08 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Arcus Biosciences NYSE:RCUS

$8.66 +0.16 (+1.82%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$8.64 -0.03 (-0.35%)

As of 06/20/2025 05:16 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time